ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO963

COVID-19 Mortality in Kidney Transplant Recipients: Analysis of Risk Factors

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Turk, Michael, Allegheny Health Network, Pittsburgh, Pennsylvania, United States
  • Alhuneafat, Laith, Allegheny Health Network, Pittsburgh, Pennsylvania, United States
  • Rizvi, Ali Waris, Allegheny Health Network, Pittsburgh, Pennsylvania, United States
  • Gupta, Naman, Allegheny Health Network, Pittsburgh, Pennsylvania, United States
  • Barnett, Katherine, Allegheny Health Network, Pittsburgh, Pennsylvania, United States
  • Gutta, Ramya, Allegheny Health Network, Pittsburgh, Pennsylvania, United States
  • Mealy, Shane, Allegheny Health Network, Pittsburgh, Pennsylvania, United States
  • Rana, Tabeer, Allegheny Health Network, Pittsburgh, Pennsylvania, United States
  • Shah, Aaisha, Allegheny Health Network, Pittsburgh, Pennsylvania, United States
  • Sharma, Alisha, Allegheny Health Network, Pittsburgh, Pennsylvania, United States
  • Osman, Omar, Allegheny Health Network, Pittsburgh, Pennsylvania, United States
  • Sureshkumar, Kalathil K., Allegheny Health Network, Pittsburgh, Pennsylvania, United States
Background

Mortality rates for COVID-19 infection vary widely. Immunocompromised patients in general have worse outcomes. We aimed to evaluate kidney transplant recipients (KTRs) who were admitted for COVID-19 infection and investigate patient specific factors or comorbidities that may have influenced mortality rates.

Methods

In this retrospective study, we identified KTRs who developed COVID-19 infection between March 2020 and January 2022 within our integrated health network. Through chart review, patient characteristics were collected and stratified by 90-day mortality.

Results

Out of 114 KTRs hospitalized with COVID-19 infection, 24 (21.0%) died during admission, and another 7 died within 90 days of admission bringing total 90-day mortality to 31/114 (27.2%). Among the114 hospitalized patients, 53 (46.5%) had received at least one prior COVID-19 vaccine dose including 35 who received two doses and 9 who received ≥3 doses. KTRs who survived following COVID-19 hospitalizations were significantly younger and were more likely to be vaccinated (Table).

Conclusion

Approximately 1 out of 4 KTRs admitted for COVID-19 infection died within 90-days. Older age was a mortality risk factor and vaccination conferred protection against mortality in these immunocompromised patients. Our study highlights the importance of vaccination in these patients. Relatively small sample size likely limited identification of other potential risk factors for mortality in our analysis.

Patient characteristics
VariablesOverall (n=114)Survived (n=83)Deceased (n=31)p-value
Age61.2 ± 11.658.7 ± 11.068.0 ± 10.5<0.001
Female sex46 (40%)30 (36%)16 (52%)0.13
White race72 (63%)53 (64%)19 (61%)0.41
Black race37 (33%)27 (33%)10 (32%)0.41
Body mass index29.9 ± 7.230.3 ± 6.728.7 ± 8.60.28
Hypertension106 (93%)76 (92%)30 (97%)0.33
Diabetes58 (51%)41 (49%)17 (55%)0.61
CAD35 (31%)23 (28%)12 (39%)0.26
Donor type: Deceased83 (73%)57 (69%)26 (84%)0.11
Donor type: Living31 (27%)26 (31%)5 (16%)0.11
IS regimen: MMF84 (74%)59 (71%)25 (81%)0.30
IS regimen: Steroids59 (52%)45 (54%)14 (45%)0.39
Vaccinated (at least 1 dose)53 (46%)43 (52%)10 (32%)0.06

CAD=coronary artery disease; IS= immunosuppression